Literature DB >> 17259997

Antiangiogenesis to treat cancer and intraocular neovascular disorders.

Farbod Shojaei1, Napoleone Ferrara.   

Abstract

Identification and characterization of several important regulators of angiogenesis, and FDA approval of the first antiangiogenic drugs, has opened a new era in the therapy of cancer and neovascular age-related macular degeneration. This brief review focuses on the progress in targeting one of the major regulators of angiogenesis, VEGF-A, and also discusses potential cellular and molecular mechanisms underlying resistance to antiangiogenic treatments.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17259997     DOI： 10.1038/labinvest.3700526

Source DB:  PubMed          Journal:  Lab Invest        ISSN： 0023-6837            Impact factor:   5.662


  17 in total

1.  Phase II and coagulation cascade biomarker study of bevacizumab with or without docetaxel in patients with previously treated metastatic pancreatic adenocarcinoma.

Authors:  Igor A Astsaturov; Neal J Meropol; R Katherine Alpaugh; Barbara A Burtness; Jonathan D Cheng; Sue McLaughlin; André Rogatko; Zhiheng Xu; James C Watson; Louis M Weiner; Steven J Cohen
Journal:  Am J Clin Oncol       Date:  2011-02       Impact factor: 2.339

2.  Neuroblastoma progression correlates with downregulation of the lymphangiogenesis inhibitor sVEGFR-2.

Authors:  Jürgen Becker; Helena Pavlakovic; Fabian Ludewig; Fabiola Wilting; Herbert A Weich; Romulo Albuquerque; Jayakrishna Ambati; Jörg Wilting
Journal:  Clin Cancer Res       Date:  2010-02-23       Impact factor: 12.531

3.  [Age-related macular degeneration and risk of stroke].

Authors:  V Biousse; M-G Bousser; A Gaudric
Journal:  J Fr Ophtalmol       Date:  2008-01       Impact factor: 0.818

4.  Nanoparticulate delivery system targeted to tumor neovasculature for combined anticancer and antiangiogenesis therapy.

Authors:  Zhe Wang; Wai-Keung Chui; Paul C Ho
Journal:  Pharm Res       Date:  2010-11-06       Impact factor: 4.200

Review 5.  [Inhibition of angiogenesis in the anterior chamber of the eye].

Authors:  F Bock; Y König; T Dietrich; P Zimmermann; M Baier; C Cursiefen
Journal:  Ophthalmologe       Date:  2007-04       Impact factor: 1.059

6.  The subconjunctival use of cetuximab and bevacizumab in inhibition of corneal angiogenesis.

Authors:  Selcuk Tunik; Yusuf Nergiz; Ugur Keklikci; Murat Akkus
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-04-15       Impact factor: 3.117

7.  Calpain inhibitors reduce retinal hypoxia in ischemic retinopathy by improving neovascular architecture and functional perfusion.

Authors:  Mien V Hoang; Lois E H Smith; Donald R Senger
Journal:  Biochim Biophys Acta       Date:  2010-09-08

8.  Targeting soluble CD146 with a neutralizing antibody inhibits vascularization, growth and survival of CD146-positive tumors.

Authors:  J Stalin; M Nollet; P Garigue; S Fernandez; L Vivancos; A Essaadi; A Muller; R Bachelier; A Foucault-Bertaud; L Fugazza; A S Leroyer; N Bardin; B Guillet; F Dignat-George; M Blot-Chabaud
Journal:  Oncogene       Date:  2016-04-11       Impact factor: 9.867

9.  Activated VEGF receptor shed into the vitreous in eyes with wet AMD: a new class of biomarkers in the vitreous with potential for predicting the treatment timing and monitoring response.

Authors:  Geetanjali Davuluri; Virginia Espina; Emanuel F Petricoin; Mark Ross; Jianghong Deng; Lance A Liotta; Bert M Glaser
Journal:  Arch Ophthalmol       Date:  2009-05

10.  In vitro angiogenesis induced by tumor-endothelial cell co-culture in bilayered, collagen I hydrogel bioengineered tumors.

Authors:  Christopher S Szot; Cara F Buchanan; Joseph W Freeman; Marissa Nichole Rylander
Journal:  Tissue Eng Part C Methods       Date:  2013-04-26       Impact factor: 3.056
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.